Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04814732 | Expanded Access Program of Surufatinib | no longer available | — | — | HutchmedINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04757259 | Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib | no longer available | — | — | Alexion Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 19, 2024 | clinicaltrials |
| NCT03914872 | Expanded Access Neoantigen Vaccine in Solid Tumors | no longer available | — | — | Washington University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05225259 | Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Feb 28, 2024 | clinicaltrials |
| NCT04446793 | Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | no longer available | — | — | Cardiff OncologyINDUSTRY | 0 | Feb 12, 2024 | clinicaltrials |
| NCT06238583 | Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors | no longer available | — | — | BayerINDUSTRY | 11 | Feb 2, 2024 | clinicaltrials |
| NCT03941782 | Compassionate Use of BYL 719 Alpelisib | no longer available | — | — | New Mexico Cancer Research AllianceOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02856438 | Early Patient Access Treatment Use Protocol CA204-220 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT02368301 | Expanded Access Treatment Protocol CA204-143 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 30, 2023 | clinicaltrials |
| NCT03138629 | Expanded Access to VAL-083 | no longer available | — | — | Kintara Therapeutics, Inc.INDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT05002465 | Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer | no longer available | — | — | Dana MathewsOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT01838187 | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | no longer available | — | — | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT02822495 | Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies | no longer available | — | — | Atara BiotherapeuticsINDUSTRY | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05415228 | Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer | no longer available | — | — | Morand Piert, MDOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT04518644 | Nilotinib, for Patients With CML-CP or CML-AP | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 28, 2023 | clinicaltrials |
| NCT04869501 | Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer | no longer available | — | — | I-Mab Biopharma US LimitedINDUSTRY | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05131438 | An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) | no longer available | — | — | EQRx International, Inc.INDUSTRY | 1 | Mar 27, 2023 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05692050 | Expanded Access to Epcoritamab | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 3, 2023 | clinicaltrials |
| NCT04825652 | 177Lu-PSMA-617 Managed Access Program for mCRPC Patients | no longer available | — | — | Advanced Accelerator ApplicationsINDUSTRY | 0 | Jan 13, 2023 | clinicaltrials |
| NCT05107193 | Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors) | no longer available | — | — | Boehringer IngelheimINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT02960620 | Therasphere for Unresectable Primary or Secondary Liver Neoplasia | no longer available | — | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT00419367 | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2022 | clinicaltrials |
| NCT04559555 | MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 9, 2022 | clinicaltrials |
| NCT04599647 | EAP for the Treatment of Glioblastoma With PVSRIPO | no longer available | — | — | Istari Oncology, Inc.INDUSTRY | 1 | Jun 29, 2022 | clinicaltrials |
| NCT04678466 | Flotetuzumab Expanded Access Program | no longer available | — | — | MacroGenicsINDUSTRY | 0 | May 31, 2022 | clinicaltrials |
| NCT05392374 | Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas | no longer available | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT03123211 | Expanded Access to Veliparib | no longer available | — | — | AbbVieINDUSTRY | 0 | May 24, 2022 | clinicaltrials |
| NCT02075177 | Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | no longer available | — | — | South Plains Oncology ConsortiumNETWORK | 1 | Mar 21, 2022 | clinicaltrials |
| NCT04289155 | Individual Patient Compassionate Use of GX-I7 | no longer available | — | — | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02258490 | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | no longer available | — | — | Emory UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT03134131 | Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas | no longer available | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT03501940 | F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | no longer available | — | — | Andrei IagaruOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT04800068 | Expanded Access [Ga-68] PSMA-11 PET Imaging | no longer available | — | — | Mayo ClinicOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03801278 | An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer(FPA144) | no longer available | — | — | Five Prime Therapeutics, Inc.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT03594162 | Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03914885 | Compassionate Use Re-Infusion of ATLCAR.CD30 | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03126617 | Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 29, 2021 | clinicaltrials |
| NCT04453397 | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | no longer available | — | — | TeneoOne Inc.INDUSTRY | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02449135 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma | no longer available | — | — | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02985658 | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | no longer available | — | — | University of WashingtonOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT01200017 | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | no longer available | — | — | Christopher DvorakOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT02354612 | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | no longer available | — | — | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Feb 15, 2021 | clinicaltrials |
| NCT02475382 | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen(CheckMate 169) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Nov 27, 2020 | clinicaltrials |
| NCT04644107 | Expanded Access for Marizomib | no longer available | — | — | CelgeneINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01151930 | Long-Term Compassionate Use Study for Continued Administration of SCB01A-01 | no longer available | — | — | SynCore Biotechnology Co., Ltd.INDUSTRY | 0 | Nov 17, 2020 | clinicaltrials |
| NCT01947608 | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 3, 2020 | clinicaltrials |
| NCT01196208 | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | no longer available | — | — | Seagen Inc.INDUSTRY | 15 | Sep 21, 2020 | clinicaltrials |
| NCT02889445 | A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers | no longer available | — | — | DEKK-TEC, Inc.INDUSTRY | 1 | Aug 18, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Apr 12, 2024source: clinicaltrials